Fridley, Minnesota–based Medtronic’s In.Pact 018 paclitaxel-coated percutaneous transluminal angioplasty (PTA) balloon catheter, a drug-coated balloon product, received an indication for the interventional treatment of peripheral arterial disease (PAD) in the superficial femoral and popliteal arteries.
According to a news release, In.Pact 018 uses the same drug coating formulation as — and was built upon equivalent technology to — the In.Pact Admiral DCB. The In.Pact 018 will be used for PTA of de novo, restenotic or in-stent restenotic lesions with lengths up to 360 mm with vessel diameters of 4-7 mm.
Get the full story at our sister site, Drug Delivery Business News.
